Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …

Abstract Development of a malaria vaccine remains a critical priority to decrease clinical
disease and mortality and facilitate eradication. Accordingly, RTS, S, a protein-subunit …

Abstract Development of a highly effective vaccine or antibodies for the prevention and
ultimately elimination of malaria is urgently needed. Here we report the isolation of a number …

Over 75% of malaria-attributable deaths occur in children under the age of 5 years.
However, the first malaria vaccine recommended by the World Health Organization (WHO) …

Immunization with attenuated Plasmodium falciparum sporozoites (PfSPZs) has been shown
to be protective against malaria, but the features of the antibody response induced by this …

Discovering potent human monoclonal antibodies (mAbs) targeting the Plasmodium
falciparum circumsporozoite protein (PfCSP) on sporozoites (SPZ) and elucidating their …

Human malaria affects the vast majority of the world's population with the Plasmodium
falciparum species causing the highest rates of morbidity and mortality. With no licensed …

Affinity maturation, the clonal selection and expansion of antigen-activated B cells
expressing somatically mutated antibody variants that develop during T cell–dependent …

Malaria is a vector-borne disease of global importance, with the vast majority of its life-
threatening cases caused by infection with Plasmodium falciparum parasites. Repeated …

Memory B cells (MBCs) epitomize the adaptation of the immune system to the environment.
We identify two MBC subsets in peripheral blood, CD27 dull and CD27 bright MBCs, whose …